Prajapati Ashwin, Gupta Srinath, Nayak Prakash, Gulia Ashish, Puri Ajay
Bone and Soft Tissue Services, Dept of Surgical Oncology, Tata Memorial Hospital, and Homi Bhabha National Institute (HBNI), Mumbai, India.
J Clin Orthop Trauma. 2021 Dec;23:101651. doi: 10.1016/j.jcot.2021.101651. Epub 2021 Oct 22.
COVID-19 pandemic has disrupted access to healthcare. Delay in diagnosis and onset of care increases cancer related mortality. We aim to analyse its impact on patient profile, hospital visits, morbidity in surgically treated patients and process outcomes.
We analysed an ambi-directional cohort from 16th March to June 30, 2020 (Pandemic cohort, PC) as compared to 2019 (Pre-pandemic cohort, PPC). We measured, new patient registrations, proportion of 'within state' patients vs 'rest of India', median time to treatment decision, proportion of patients seeking 'second opinions', modality of initial treatment (surgery/radiotherapy/chemotherapy), 30-day post-operative morbidity/mortality and conversion of inpatient-to 'teleconsult' in the PC.
Between the 2 cohorts, new registrations declined from 235 to 69 (70% reduction). The percentage of 'within state' patients increased from 41.7% to 53.6% (11.9% increase). There was a decline in second opinion consults from 25% to 16%. The median time to decision-making decreased to 16 days in PC vs 20 days in PPC (20% reduction). Surgery was the first line of treatment in 40% as compared to 34% in the PPC with a mean time to surgery of 24 days in PC compared to 36 days in PPC (33% reduction). 66 surgeries were performed in the PC compared to 132 in the PPC. Thirty day post operative morbidity needing readmission remained similar (18% PC, vs 17% PPC). Perioperative intensive care remained similar in both cohorts. Teleconsultation was deemed medically safe in 92.8% (439/473 patients).
The COVID 19 pandemic has substantially reduced access and onset to cancer care. Post operative morbidity and mortality did not seem to worsen with triage. Teleconsultation is an effective tool in optimizing follow up strategy.
新冠疫情扰乱了医疗服务的获取。诊断和治疗开始的延迟增加了癌症相关死亡率。我们旨在分析其对患者特征、医院就诊情况、接受手术治疗患者的发病率以及治疗过程结果的影响。
我们分析了一个双向队列,将2020年3月16日至6月30日的队列(疫情队列,PC)与2019年的队列(疫情前队列,PPC)进行比较。我们测量了新患者登记情况、“本州内”患者与“印度其他地区”患者的比例、治疗决策的中位时间、寻求“二次诊断意见”的患者比例、初始治疗方式(手术/放疗/化疗)、术后30天的发病率/死亡率以及疫情队列中住院患者向“远程会诊”的转变情况。
在这两个队列之间,新登记患者从235例降至69例(减少了70%)。“本州内”患者的百分比从41.7%增至53.6%(增加了11.9%)。二次诊断意见咨询从25%降至16%。疫情队列中决策的中位时间降至16天,而疫情前队列中为20天(减少了20%)。40%的患者将手术作为一线治疗方式,疫情前队列中这一比例为34%,疫情队列中手术的平均时间为24天,而疫情前队列为36天(减少了33%)。疫情队列中进行了66例手术,疫情前队列为132例。术后30天因需再次入院的发病率保持相似(疫情队列18%,疫情前队列17%)。两个队列的围手术期重症监护情况相似。92.8%(439/473例患者)的远程会诊被认为在医学上是安全的。
新冠疫情大幅减少了癌症治疗的可及性和治疗开始时间。术后发病率和死亡率似乎并未因分诊而恶化。远程会诊是优化随访策略的有效工具。